treatment

LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE

Results presented at the 17th World Stroke Congress (WSC 2025) LT3001(Odatroltide)-202 phase 2b study met primary endpoint. No symptomatic intracranial…

1 month ago

Xinhua Silk Road: Innovation, tradition deeply integrated on TCM trade fair in China’s Zhangshu City

BEIJING, Oct. 28, 2025 /PRNewswire/ -- China's Zhangshu City, a famed industrial hub of traditional Chinese medicine (TCM) for centuries, has actively…

1 month ago

FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

October 31, 2025 16:30 ET  | Source: FibroBiologics, Inc. Advancing preparations to begin manufacturing of fibroblast-based spheroids product candidate, CYWC628,…

2 months ago

Bright Minds Biosciences toPresent at Upcoming Conferences

October 30, 2025 18:30 ET  | Source: Bright Minds Biosciences NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Bright Minds…

2 months ago

South Korea’s Leading Hair Loss Treatment Company, AESMED Co., Ltd., to Participate in Cosmoprof Asia Hong Kong 2025

AESMED to Focus on Promoting the 1111 Hair Care Day Campaign SEOUL, South Korea, Oct. 28, 2025 /PRNewswire/ -- AESMED…

2 months ago

Health Canada Grants Authorization for LEQEMBI (lecanemab) for the Treatment of Early Alzheimers Disease

In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or…

2 months ago

Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3K Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglyc

Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT signaling in tumor cells without affecting glucose metabolismRobust…

2 months ago

Berlin Heals Welcomes Dr. Eric Fain as New Board Member

Berlin Heals adds MedTech Veteran Dr. Eric Fain to Board of Directors Dr. Fain brings over 35 years of strategic…

2 months ago

Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference

October 24, 2025 07:00 ET  | Source: Sagimet Biosciences Inc. Denifanstat met all primary and secondary endpoints versus placebo and…

2 months ago